Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

Abstract Background Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the first specific migraine prophylactic medication. Erenumab is the only CGRP mAB targeting the CGRP receptor. Clinical data regarding efficacy and tolerability of erenumab in highly therapy-refractory patien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Armin Scheffler, Olga Messel, Sebastian Wurthmann, Michael Nsaka, Christoph Kleinschnitz, Martin Glas, Steffen Naegel, Dagny Holle
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2020-07-01
Colecção:The Journal of Headache and Pain
Assuntos:
1. migraine
2. erenumab
3. therapy
4. real-world
5. CGRP antibody
Acesso em linha:http://link.springer.com/article/10.1186/s10194-020-01151-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados